Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 23;10(11):1294.
doi: 10.3390/antibiotics10111294.

Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent

Ching-Chi Lee  1   2 , Chih-Chia Hsieh  3 , Wen-Chien Ko  2   4
Affiliations

Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent

Ching-Chi Lee et al. Antibiotics (Basel). .

Abstract

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and prevent progression to severe illness. Molnupiravir (formerly EIDD-2801), a prodrug of beta-d-N4-hydroxycytidine (EIDD-1931) and an inhibitor of RNA-dependent RNA polymerase, possesses significant activity against SARS-CoV-2. Its prophylactic efficacy has been evidenced in a ferret model. Two phase-I trials (NCT04392219 and NCT04746183) have demonstrated that oral molnupiravir is safe and well-tolerated at therapeutic doses. After five-days of oral molnupiravir therapy, satisfactory efficacies, assessed by eliminating nasopharyngeal virus in patients with early and mild COVID-19, were disclosed in two phase-II trials (NCT04405739 and NCT04405570). Two phase-II/III trials, NCT04575597 and NCT04575584, with estimated enrollments of 1850 and 304 cases, respectively, are ongoing. The NCT04575597 recently released that molnupiravir significantly reduced the risk of hospitalization or death in adults experiencing mild or moderate COVID-19. To benefit individual and public health, clinical applications of molnupiravir to promptly treat COVID-19 patients and prevent SARS-CoV-2 transmission may be expected.

Keywords: COVID-19; RNA polymerase inhibitor; antiviral agents; clinical trial; molnupiravir.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
In plasma, molnupiravir is rapidly converted to EIDD-1931, which is converted into EIDD-1931-triphosphate, the active antiviral compound, after penetration into SARS-CoV-2-infected cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhang L., Shen F.-M., Chen F., Lin Z. Origin and evolution of the 2019 novel coronavirus. Clin. Infect. Dis. 2020;71:882–883. doi: 10.1093/cid/ciaa112. - DOI - PMC - PubMed
    1. Chan J.F.-W., To K.K.-W., Tse H., Jin D.-Y., Yuen K.-Y. Interspecies transmission and emergence of novel viruses: Lessons from bats and birds. Trends Microbiol. 2013;21:544–555. doi: 10.1016/j.tim.2013.05.005. - DOI - PMC - PubMed
    1. Memish Z.A., Zumla A.I., Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.M. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 2013;368:2487–2494. doi: 10.1056/NEJMoa1303729. - DOI - PubMed
    1. Zhong N., Zheng B., Li Y., Poon L., Xie Z., Chan K., Li P., Tan S., Chang Q., Xie J. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362:1353–1358. doi: 10.1016/S0140-6736(03)14630-2. - DOI - PMC - PubMed
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. - DOI - PMC - PubMed

LinkOut - more resources

-